Global Autoimmune Disease Treatment Market Size, Forecast, and Trend Highlights Over 2025-2037
Autoimmune Disease Treatment Market size was valued at USD 153.5 billion in 2024 and is projected to reach USD 343.1 billion by the end of 2037, rising at a CAGR of 7.8% during the forecast period, i.e., 2025-2037. In 2025, the industry size of autoimmune disease treatment is evaluated at USD 165 billion.
According to the WHO, the occurrence rate of autoimmune diseases, such as rheumatoid arthritis, psoriasis, and type I diabetes, around the world ranges between 5.1% and 10.3%. It also mentioned that the population of such patients in Europe crossed 12.8 million, where Germany and France accounted for 5.3 million and 3.9 million, respectively. This expanding demography is further creating a surge in innovative therapies, including biologics and immunosuppressants, fostering a substantial demand in the autoimmune disease treatment market. Moreover, advancements in diagnostic accuracy and widespread awareness about early prevention are accumulatively propelling cash inflow in this sector.
The ongoing inflation in raw material costs, R&D expenses, and regulatory compliance is escalating the key economic indicators in the autoimmune disease treatment market. In this regard, between 2023 and 2024, the U.S. Bureau of Labor Statistics (BLS) observed a 4.3% year-over-year (YoY) rise in the producer price index (PPI) for associated medications. Simultaneously, this upward trajectory followed through the consumer price index (CPI) for retailed products from this sector, with a 5.9% increase. Thus, despite the growing demand, a financial barrier is present across the globe due to the heightening payers' pricing volatilities for API, labor, and logistics. Furthermore, the collective efforts from both government and drug developers are being concentrated on maintaining comprehensive pricing.
